Fig. 4From: A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?Strategies by therapeutic area in a guidelines, b sponsor documentations and c regulatory questions. CNS, central nervous system; CVD, cardiovascular diseases; Onco, oncology; Resp, respiratory diseasesBack to article page